In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cappella: Can a New Twist On An Old Idea Solve the Bifurcation Challenge?

Executive Summary

Device companies large and small have failed repeatedly in efforts to address bifurcations, which remain one of the largest unmet opportunities in cardiology. Cappella thinks it can solve the problem with a device that's a new version of an old idea, reversing current protocol to treat the side branch first.
Advertisement

Related Content

Stentys' Shifting Focus: Moving Beyond Bifurcations, Stenting for AMI
Invatec: Translating Global Success in Vascular Devices to the US Market
Boston Scientific Looks to Next-Generation DES with Labcoat Deal
Minvasys: Tailoring the Stent to Fit the Lesion in Bifurcations
Stentys SAS
Invatec: From Garage to Global Cardiology Brand
Bifurcation Stenting: The Next Generation
Cappella Inc.
Labcoat: Less is more in Next Generation Drug-Eluting Stents
Invatec: Italy's Home-Grown Device Model

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003492

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel